Ipsen, Skyhawk in RNA targeting research collaboration in rare neurological diseases

 

• Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration
• Following development candidate validation, Ipsen will assume responsibility for further development and commercialization, leveraging existing neuroscience expertise in movement disorders
• This promising platform technology created by Skyhawk allows for the exploration of previously undruggable RNA targets with small molecules, expanding the disease target landscape

https://www.biospace.com/article/releases/ipsen-and-skyhawk-therapeutics-announce-rna-targeting-research-collaboration-in-rare-neurological-diseases/